UBT251 (Compound 3): what the full obesity paper and its supplement show

| Trial results

The Cell Metabolism paper on UBT251 in adults with overweight or obesity is now available in full, with a supplement. The supplement prints the molecule's sequence, chemical formula and weight, which the Atlas earlier listed as unpublished, and it shows which dose group produced which result.

Searching for "Vistrutide"? Some sellers list a product under that name. It is not an official name, the paper does not use it, and whether those listings match the structure below has not been established.

What the supplement shows

UBT251 sequence mapThe 39-residue sequence of UBT251 as printed in the supplement of Zhou et al., Cell Metabolism. Modified residues are highlighted and the lipid side chain is shown on lysine 17.UBT251: the printed sequence, residue by residue39 residues, amidated C-terminus. Source: Document S1 of Zhou et al., Cell Metabolism, online October 8, 2026, DOI 10.1016/j.cmet.2026.09.021Y1Aib2Q3G4T5αMeF6T7S8D9Y10S11I12αMeL13L14D15K16K17A18Q19Aib20A21F22I23E24Y25L26L27E28S29H30P31S32S33G34A35P36P37Ac3c38S39NH₂AEEAAEEAγ-GluC20 diacidLipid chain on lysine 17, backbone end on the right:Non-standard residue (Aib, αMePhe, αMeLeu, Ac3c)Lysine 17 and its lipid chainFormula C232H359N49O72 · MW 4986.70 (as printed)
The printed sequence from the supplement: modified residues highlighted, lipid chain on lysine 17. Formula C232H359N49O72, weight 4986.70.

UBT251 is a development code with no official nonproprietary name. It is also searched online as Compound 3, a label from community comparisons with the developer's patent filings that the paper itself does not use. Novo Nordisk is reported to hold rights outside Greater China.

What the trial found

QuestionWhat the paper reports
Who took part205 adults in China with overweight or obesity and no diabetes, average age 34. 51 got 2 mg, 25 got 4 mg starting at 0.5 mg, 25 got 4 mg starting at 1 mg, 54 got 6 mg and 50 got placebo, once a week for 24 weeks. Everyone also followed a diet and exercise program.
Average weight change at week 24Down 13.6% on 2 mg, 16.2% and 19.7% on the two 4 mg groups, and 18.7% on 6 mg, versus 2.0% on placebo. The 19.7% came from a 25-person group, so the authors caution it may not be a true dose response.
Common side effectsDiarrhea 35.5% (10.0% on placebo), decreased appetite 23.9% (8.0%), nausea 14.2% (4.0%) and vomiting 13.5% (4.0%). One person stopped because of a side effect. Heart rate rose during treatment and came back toward baseline after stopping. Serious events were rare and judged unrelated.

What the structure tells us

UBT251 is a 39-amino-acid peptide with a fatty side chain on lysine 17, a design shared with approved once-weekly medicines. It is investigational and not approved anywhere.

What is still unknown

How long it stays in the body, results beyond 24 weeks, data outside China, and any head-to-head comparison. The trial was run by the developer, and the authors include employees of the developer and of Novo Nordisk.

Trial amounts (not recommendations)

Figures below summarize amounts and schedules reported in published research or circulating online. Listing a figure documents what is reported; it is not a recommendation and does not show a regimen is safe, effective, or appropriate for any person.

GroupWeekly amounts (steps about every 4 weeks)
2 mg group0.5, 1, then 2 mg
4 mg group, start 0.50.5, 1, 2, then 4 mg
4 mg group, start 11, 2, then 4 mg
6 mg group1, 2, 4, then 6 mg

Source for the amounts: Table S5 of the supplement. Subcutaneous, once weekly, 24 weeks.

Worth knowing: This is one placebo-controlled trial run in China. It shows how UBT251 compares with placebo, not how it compares with other weight-loss medicines.

Related: UBT251 medicine page | Earlier news on the two UBT251 papers | PeptideBlog write-up with the full sequence

Source: Zhou Z, et al. UBT251 in adults with overweight or obesity, Cell Metabolism, online October 8, 2026 Journal article. Supplemental information (Document S1) Journal supplement. ClinicalTrials.gov record NCT07177469 Trial registry.

More news

All news | What changed lately | Subscribe by RSS | About the Atlas

Not medical advice. News items describe what was announced or published. They do not say whether a medicine is right for you. A licensed clinician who knows your history does.